ArticleJournal of virology2026
GRP78 promotes rabies virus entry through interacting with viral receptors.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The rabies virus (RABV) is known to have four potential receptors, including the nicotinic acetylcholine receptor (nAChR), neural cell adhesion molecule (NCAM), low-affinity nerve growth factor receptor (NGFR), and metabolic glutamate receptor 2 (mGluR2). However, the regulatory mechanism that maintains the stability of these receptors on the cell membrane remains unclear. In this study, we found that 78 kDa glucose-regulated protein (GRP78) is required for RABV infection in cells. Knockdown of GRP78 decreased the internalization of RABV. A GRP78 monoclonal antibody effectively blocked RABV infection. Mechanistically, GRP78 interacts with RABV candidate receptors directly through the 19 to 50 amino acids at the N-terminal of GRP78, which is crucial for RABV infection. GRP78 can form complexes with viral receptors and viral envelope glycoproteins on the cell membrane. Silencing GRP78 led to a decrease in the expression of RABV candidate receptors on the cell membrane. Our findings suggest that GRP78 plays a critical role in stabilizing the cell-surface expression of these receptors by directly interacting with them, which in turn facilitates the internalization of RABV. These findings provide new insights into the complex process of RABV invasion into cells and may contribute to the development of therapeutics against RABV. IMPORTANCE: Rabies virus (RABV) is a neglected but fatal zoonotic virus. Research has shown that the RABV glycoprotein binds to cell receptors and, with host factors' cooperation, invades cells to initiate its life cycle. Although several potential receptors and host factors for RABV have been identified, the process of virus invasion remains unclear. Here, we report that GRP78 has a significant inhibitory effect on RABV infection and plays a crucial role in its early stage, particularly during virus internalization. Furthermore, we found that GRP78 directly interacts with all candidate receptors of RABV, and this interaction is critical for virus internalization. Our study reveals how GRP78 mediates RABV invading cells and deepens our understanding of host-virus interaction mechanisms during RABV infection, providing a promising target for preventing and treating rabies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.